CALCINEURIN INHIBITOR MARKET ANALYSIS

Calcineurin Inhibitor Market, By Drug Type (Cyclosporine, Tacrolimus, Pimecrolimus, Voclosporin, and Others), By Route of Administration (Oral, Topical, and Intravenous), By Indication (Organ Transplant Rejection Prevention, Autoimmune Diseases, Ophthalmic Diseases (Dry Eye Syndrome, Uvei, Other Dermatological Conditions), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Specialty Clinics, Dermatology Centers, Transplant Centers), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Global Calcineurin Inhibitor Market- Recent Developments

New Product Launches

In June 2020, Sandoz, a Novartis division and a global leader in generic pharmaceuticals and biosimilars, announced the launch of once-daily generic tacrolimus capsules known as Dailiport in Germany, the U.K., The Netherlands, Finland, Sweden, Estonia, Latvia, and Slovakia, and as Conferoport in Italy and Spain
In November 2020, Glenmark Pharmaceuticals Ltd. (GPL), a global research-led pharmaceutical company, had been granted final approval by the U.S. Food and Drug Administration (U.S. FDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg, the generic version of Prograf Capsules, 0.5 mg, 1 mg and 5 mg, of Astellas Pharma US, Inc.
On November 25, 2020, Lupin Limited, a pharmaceutical company, announced the launch of Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, after Lupin’s alliance partner Concord Biotech Limited, a Biotechnology company, received an approval for its Abbreviated New Drug Application from the U.S. FDA

Acquisition and Agreement

In January 2022, Aequus Pharmaceuticals Inc., a growing specialty pharmaceutical company, announced that it had agreed to an extension of terms for its promotional service agreement with Sandoz, a global leader in generic pharmaceuticals and biosimilars, on Tacrolimus immediate-release to December 31, 2022. Aequus began Canadian promotional efforts in 2016 for Sandoz’s generic Tacrolimus. Through targeted awareness, valued added services, and customized support for both provincial and transplant center stakeholders, Aequus had achieved a 4-Year CAGR of almost 20% for the Sandoz Tacrolimus brand.
On March 11, 2022, Pfizer Inc., a pharmaceutical and biotechnology company has announced the complete acquisition of Arena Pharmaceuticals, a clinical-stage company developing innovative potential therapies for the treatments for therapeutic areas such as gastroenterology, dermatology, and cardiology, and immunology